Lidocaine suppresses HER2-positive breast cancer cell proliferation by targeting the OGT-CCNL1 axis.

ABSTRACT:

Background

HER2-positive breast cancer, known for its heterogeneity and complex molecular mechanisms, poses a significant therapeutic challenge. Lidocaine, a widely used local anesthetic, has recently been identified as a potential anticancer agent. This study investigates the effects of lidocaine on HER2-positive breast cancer proliferation and the underlying mechanisms.

Methods

The effects of lidocaine on cell proliferation, cell cycle distribution, and O-GlcNAcylation levels in AU565 and BT474 cells were assessed using CCK-8 assays, EdU incorporation assays, flow cytometry, and western blot analysis. Furthermore, the interaction between lidocaine and OGT was examined using molecular docking and co-immunoprecipitation (co-IP) experiments.

Results

Lidocaine was found

SUBMITTER: Sun Y 

PROVIDER: S-EPMC12796022 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature